
European stock exchanges mull 24-hour trading to attract retail investors amid U.S. boom

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hamilton Spectator
3 minutes ago
- Hamilton Spectator
Weston family wants to buy Hudson's Bay charter for $12.5 million and donate it: docs
TORONTO - The royal charter that formed Hudson's Bay about 355 years ago could soon be getting a new home. The Canadian Museum of History announced Wednesday that Wittington Investments Ltd., a private Canadian holding company for the Weston family, wants to buy the document for $12.5 million and donate it to the Quebec institution. The charter was signed by King Charles II in 1670. It gave the Bay rights to a vast swath of land spanning most of Canada and extraordinary power over trade and Indigenous relations for decades more. The museum says the acquisition still needs court approval but if that is obtained, the Westons will donate the document immediately and permanently. 'At a time when Canada is navigating profound challenges and seeking renewed unity, it is more important than ever that we hold fast to the symbols and stories that define us as a nation,' said Galen Weston in a statement. 'The Royal Charter is an important artifact within Canada's complex history. Our goal is to ensure it is preserved with care, shared with integrity, and made accessible to all Canadians, especially those whose histories are deeply intertwined with its legacy.' His family made its fortune through Canadian retail chains including Holt Renfrew, as well as several European department stores. As part of its proposed purchase of the charter, the family has offered $1 million in additional funding. The museum said it will support 'a meaningful consultation process' with Indigenous Peoples on how the Royal Charter 'can be shared, interpreted and contextualized in a manner that respects Indigenous perspectives and historical experiences.' The funding will help the museum share the charter with other museums and through public exhibitions. Caroline Dromaguet, the museum's president and CEO, said the donation is of 'enormous importance to Canada' and 'will serve as a catalyst for national dialogue, education and reconciliation for generations to come.' The Westons expressed an interest in the charter in May, after the Bay filed for creditor protection in March under the weight of $1.1 billion in debt. It made a formal offer by June. The Bay was drawn to the $12.5 million offer because it 'substantially' exceeded the value the charter had been given during a 2022 insurance appraisal, said Adam Zalev, co-founder of Bay financial advisor Reflect Advisors, in a court filing made Wednesday. The Bay also liked the offer because of the additional funding to ensure Indigenous communities and archival institutes have access to the charter. The charter was originally due to be sold during a future auction the Bay was preparing to run with Heffel Gallery to sell 2,700 artifacts and 1,700 art pieces the retailer owned. A court motion filed Wednesday asks a judge to approve the removal of the charter from any eventual auction. When the Bay first floated the idea of running an auction to offload its treasures, it sparked concern from archival institutions, governments and Indigenous groups, including the Assembly of Manitoba Chiefs. They worried it would allow pieces of Canadian and Indigenous history to wind up in private hands and away from public view. To quell their concerns, the Bay started allowing groups to view an inventory of the collection if they sign non-disclosure agreements. A source familiar with the Bay's collection, who was not authorized to speak publicly, told The Canadian Press previously that paintings, point blankets, paper documents and even collectible Barbie dolls are part of the trove. Historians believe the charter is likely the most coveted piece the retailer owned. 'It's 100 per cent their crown jewel,' said Cody Groat, a historian of Canadian and Indigenous history who serves as the chair of the UNESCO Memory of the World Advisory Committee in an April interview. 'There is no doubt this is the most significant document that the Hudson's Bay Company has access to or that they've ever produced.' Thomas Caldwell, CEO of Toronto investment manager Urbana Corp., agreed. He told The Canadian Press in the spring that he was interested in purchasing and giving the parchment document with a royal wax seal to a museum. At the time, he said donating the piece would 'make more sense' for whoever buys it because 'it's a big hassle to have something historic like that in an office or in a home.' He speculated that it would need to be insured, have constant security and likely require storage in precise temperatures to preserve it. For many years, the Bay kept the royal charter at its head office in Toronto, but Zalev said it was recently moved to 'a secure facility specifically equipped to store and protect important documents, art and artifacts.' The charter was temporarily loaned to the Manitoba Museum in 2020. That museum and the Archives of Manitoba hold the bulk of the Bay's artifacts. The company donated them to the organizations in the 1990s, so many thought they'd be a natural home for the charter. 'We think of (the charter) as part of our records in a way already because ... we've got the rest of the story and so we feel like it makes sense for the charter to be here and to be as publicly accessible as any of the other records,' Kathleen Epp, keeper of Manitoba's Hudson's Bay Co. archives, told The Canadian Press in April. This report by The Canadian Press was first published July 30, 2025.
Yahoo
9 minutes ago
- Yahoo
AstraZeneca seeks US drug price cuts amid expansion plans, strong demand
By Pushkala Aripaka and Maggie Fick (Reuters) -AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 billion investment to expand there, as President Donald Trump pressures pharmaceuticals companies to lower costs. Speaking to journalists after second-quarter revenue and profit beat expectations, CEO Pascal Soriot said Trump's administration was reviewing the company's proposals. He did not specify which drugs were included. Trump has repeatedly threatened tariffs as he also pushes drugmakers to reduce prices to what other countries pay. However, he signalled earlier this month that companies would be given a year to 18 months to "get their act together" before any sector-specific levies take effect. "We definitely support the idea of rebalancing with some reduction of pricing levels in the U.S., and some increase, we're not talking about massive increases, in Europe," AstraZeneca's Soriot said. He added he expects all medicines for U.S. patients to be produced locally within a few months, and is also considering selling some medicines to customers directly. AstraZeneca shares rose as much as 3% after its results, but pared some gains to trade up 1.6% by 1214 GMT. "The big uncertainty, unsurprisingly, remains U.S. tariffs and Most Favoured Nation pricing in the pharmaceutical sector. AstraZeneca has looked to get ahead of this uncertainty," said Sheena Berry, a healthcare analyst at Quilter Cheviot. The U.S. accounted for more than 40% of AstraZeneca's revenue in 2024. The UK's largest-listed company by market value had prioritised the U.S. market - the world's largest, worth $635 billion - even before Trump's return to office. US BOOST AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease medicines drove total revenue for the second quarter 11% higher to $14.46 billion, on a constant currency basis. It logged double-digit growth in the U.S. despite headwinds from changes in U.S. Medicare price negotiations, while sales of cancer drugs including Tagrisso, Lynparza, Calquence, Truqap and Imfinzi beat expectations. Core earnings stood at $2.17 per share. Analysts were expecting $2.16, from $14.15 billion in sales, according to a company-provided consensus. AstraZeneca is betting on a wave of expected launches of 20 new medicines and its U.S. expansion to reach $80 billion in annual revenue by 2030 and offset generic competition. On Tuesday, it maintained its 2025 outlook and increased its interim dividend by 3%. The drugmaker in April forecast only a limited impact from potential U.S. tariffs, adding it would be able to meet its annual outlook if the levies on European imports were similar to those in other industries. A European Union-U.S. trade deal over the weekend will result in a 15% tariff on most goods, including pharmaceuticals, from the region.
Yahoo
21 minutes ago
- Yahoo
Figma's IPO date is close. The stock could trade even higher after the design startup's latest move
Collaborative design software company Figma has increased the price target for its highly anticipated initial public offering (IPO). Shares are now expected to be priced between $30 and $32 each, up from the previously disclosed price target range of $25 and $28 each. The real reason a staggering 40% of U.S. homeowners are mortgage-free Figma's IPO date is close. The stock could trade even higher after the design startup's latest move Tsunami warning tracker: Map and online tool let you follow alerts in real time after massive earthquake The cloud-based interface design tool is aiming for a valuation of around $18.8 billion, dramatically higher than last week's projection but still below the $20 billion that Adobe had planned to pay for the company a few years ago. Figma disclosed the expected price target increase on Monday in an amended registration statement with the Securities and Exchange Commission (SEC). The San Francisco-based company confidentially filed an initial S-1 form with the SEC in April. On July 1, Figma announced its registration statement was available to the public. IPO market is heating up this year Figma will trade on the New York Stock Exchange (NYSE) under the ticker 'FIG.' The listing, reportedly expected this week, could be among the year's biggest. It comes as the market for tech-focused offerings has been roaring back to life. Circle Internet Group, Chime Financial, and Hinge Health are among the buzzy tech startups that have gone public this year. In addition to Figma, space tech company Firefly Aerospace is also expected to IPO soon. In September 2022, Adobe (NYSE: ADBE) had announced plans to buy Figma for $20 billion in cash and stock. But the merger was scrapped due to antitrust concerns raised by European and U.K. regulators. In December 2023, both companies announced that they had mutually agreed to terminate their merger agreement. Adobe paid Figma a $1 billion termination fee. In its SEC paperwork, Figma reported $228.2 million in revenue for the first three months of 2025. The company reported $749 million in revenue in 2024, an increase of 48% year-over-year. The design software maker has 13 million monthly active users. This post originally appeared at to get the Fast Company newsletter: Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data